Sobi has hit the acquisition trail with a deal to buy Arthrosi Therapeutics for up to $1.5 billion, adding a drug in late-stage clinical testing for gout. The deal, which includes a sizeable $950 ...

STOCKHOLM, Jan. 15, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO: SOBI) announces today that revenue and adjusted EBITA margin for the full year 2025 were higher than previous ...

Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) announces today that revenue and adjusted EBITA margin for the full year 2025 were higher than previous outlook. Full-year revenue was ...

STOCKHOLM, Jan. 14, 2026 /PRNewswire/ -- Sobi plans to publish its report for the fourth quarter and full year of 2025 on 5 February 2026 at 08:00 CET. Investors, analysts, and the media are invited ...

STOCKHOLM, Jan. 7, 2026 /PRNewswire/ -- Sobi (STO: SOBI) today announced that topline results from the Phase 2a EMBRACE study evaluating Gamifant (emapalumab) for interferon-gamma (IFN?)-driven sepsis ...

Sobi has entered into an agreement to acquire Arthrosi Therapeutics, a private late-stage biotechnology company specialising in the development of a treatment for gout. The acquisition will strengthen ...

Expands Sobi’s pipeline with a highly differentiated new Phase 3 asset in Gout Acquisition expected to be highly accretive to Sobi’s mid- to long-term growth and margin trajectory Sobi® (STO:SOBI) has ...

Sobi, which currently has a drug under FDA review as a later line of therapy for gout, is paying $950 million to acquire Arthrosi Therapeutics, a startup with a gout drug candidate in Phase 3 ...

SAN DIEGO - Swedish pharmaceutical company Sobi (STO:SOBI) announced Monday it has entered into a definitive agreement to acquire Arthrosi Therapeutics for $950 million upfront, with potential ...

Fresh off a $153 million series E round, Arthrosi Therapeutics is skipping an IPO route and is instead being bought up for a potential value of $1.5 billion from Swedish biopharma Sobi. Under the deal ...

(RTTNews) - Swedish Orphan Biovitrum AB (SOBI.ST) has entered into an acquisition agreement with Arthrosi Therapeutics, which was invested in and incubated by Viva Biotech Holdings. Sobi will pay up ...

Swedish Orphan Biovitrum (Sobi) has signed an agreement for the acquisition of US-based biotechnology company Arthrosi Therapeutics, a move that will expand Sobi’s presence in the gout treatment ...